- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Antibody therapy developer Electra Therapeutics upsizes IPO seeking nearly $350M | 4 | Seeking Alpha | ||
| Fr | Antibody biotech Electra Therapeutics prices upsized IPO at $15 midpoint | 2 | Renaissance Capital | ||
| Fr | Inflammation biotech Electra Therapeutics charges up with $350M from upsized IPO | 1 | FierceBiotech | ||
| ELECTRA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Electra Therapeutics amasses $350M in biotech's latest big IPO | 5 | BioPharma Dive | ||
| Fr | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | 184 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| Do | Börsengang von Electra Therapeutics: Preis dürfte über Mitte der Spanne liegen | 1 | Investing.com Deutsch | ||
| Do | Dear Future Electra Therapeutics Stock Fans, Mark Your Calendars for Sept. 18 | 1 | Barchart.com | ||
| Di | Electra Therapeutics targets $342m IPO to fund hyperinflammatory syndrome drug's pivotal trials | 1 | Pharmaceutical Technology | ||
| Di | Electra Therapeutics sets terms for IPO, hoping to raise up to $347m | 3 | pharmaphorum | ||
| Mo | Electra Therapeutics aims for $342M IPO to power inflammatory drug's push through phase 3 | 1 | FierceBiotech | ||
| Mo | Antibody biotech Electra Therapeutics sets terms for $325 million IPO | 2 | Renaissance Capital | ||
| Mo | Electra Therapeutics targets $977.6 million valuation in US IPO | 1 | Reuters | ||
| Mo | Electra Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 28.08. | Electra Therapeutics beantragt Börsengang zur Finanzierung von Medikamenten gegen Immunerkrankungen | 5 | Investing.com Deutsch | ||
| 22.10.25 | EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics | 989 | PR Newswire | Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with serious immunological and cancer-related diseases
Financing was co-led by... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | +0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | +0,04 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern | ||
| RECURSION PHARMACEUTICALS | 3,830 | 0,00 % | Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript |
Das Unternehmen ELECTRA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,89 % bei einem Aktienkurs von 13,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELECTRA THERAPEUTICS INC finden Sie auf Wallstreet Online.